Het ontstaan van immuuncomplexen van infliximab en anti-infliximab als een verklaring voor het falen van infliximabtherapie bij reumatoïde artritis: observationeel onderzoek bij 4 patiënten

C. J. van der Laken; A. E. Voskuyl; J. C. Roos; M. Stigter van Walsum; E. R. de Groot; G. J. Wolbink; B. A. C. Dijkmans; L. A. Aarden

Het ontstaan van immuuncomplexen van infliximab en anti-infliximab als een verklaring voor het falen van infliximabtherapie bij reumatoïde artritis: observationeel onderzoek bij 4 patiënten

C. J. van der Laken, A. E. Voskuyl, J. C. Roos, M. Stigter van Walsum, E. R. de Groot, G. J. Wolbink, B. A. C. Dijkmans, L. A. Aarden

Research output: Contribution to journal › Article › Professional

2 Citations (Scopus)

Abstract

OBJECTIVE: To investigate the in vivo mechanism of non-responding to infliximab treatment of patients with rheumatoid arthritis (RA) and the role of anti-infliximab antibodies by using radiolabeled infliximab. DESIGN: Descriptive and comparative study. METHOD: Two responding and two non-responding RA patients were infused with radiolabeled infliximab. Subsequently imaging investigations and serum analysis were performed at set times. RESULTS: The scintigrams showed that the labelled infliximab was mainly present in the blood until 24 h after infusion. There was a trend of faster blood clearance and higher liver and spleen uptake of 99mTc-infliximab in one non-responding patient. Labelled infliximab was taken up by inflamed joints. The anti-infliximab level was high (1008 and 1641 U/ml) in the non-responders and low or not detectable in the responders. Sucrose gradients of serum revealed antibody complexes in both non-responders. Various sizes of antibody complexes, including very large ones, were observed in one non-responder who developed a serious infusion reaction. CONCLUSION: Infliximab-anti-infliximab immune complexes were found to form in RA non-responders due to the presence of significant quantities of anti-infliximab. This finding may partly explain the failure of the infliximab treatment

Original language	Dutch
Pages (from-to)	1672-1677
Journal	Nederlands Tijdschrift voor Geneeskunde
Volume	152
Issue number	30
Publication status	Published - 2008

Cite this

van der Laken, C. J., Voskuyl, A. E., Roos, J. C., Stigter van Walsum, M., de Groot, E. R., Wolbink, G. J., Dijkmans, B. A. C., & Aarden, L. A. (2008). Het ontstaan van immuuncomplexen van infliximab en anti-infliximab als een verklaring voor het falen van infliximabtherapie bij reumatoïde artritis: observationeel onderzoek bij 4 patiënten. Nederlands Tijdschrift voor Geneeskunde, 152(30), 1672-1677.

@article{8dc08c190c71497daf1197112dc6e65e,

title = "Het ontstaan van immuuncomplexen van infliximab en anti-infliximab als een verklaring voor het falen van infliximabtherapie bij reumato{\"i}de artritis: observationeel onderzoek bij 4 pati{\"e}nten",

abstract = "OBJECTIVE: To investigate the in vivo mechanism of non-responding to infliximab treatment of patients with rheumatoid arthritis (RA) and the role of anti-infliximab antibodies by using radiolabeled infliximab. DESIGN: Descriptive and comparative study. METHOD: Two responding and two non-responding RA patients were infused with radiolabeled infliximab. Subsequently imaging investigations and serum analysis were performed at set times. RESULTS: The scintigrams showed that the labelled infliximab was mainly present in the blood until 24 h after infusion. There was a trend of faster blood clearance and higher liver and spleen uptake of 99mTc-infliximab in one non-responding patient. Labelled infliximab was taken up by inflamed joints. The anti-infliximab level was high (1008 and 1641 U/ml) in the non-responders and low or not detectable in the responders. Sucrose gradients of serum revealed antibody complexes in both non-responders. Various sizes of antibody complexes, including very large ones, were observed in one non-responder who developed a serious infusion reaction. CONCLUSION: Infliximab-anti-infliximab immune complexes were found to form in RA non-responders due to the presence of significant quantities of anti-infliximab. This finding may partly explain the failure of the infliximab treatment",

author = "{van der Laken}, {C. J.} and Voskuyl, {A. E.} and Roos, {J. C.} and {Stigter van Walsum}, M. and {de Groot}, {E. R.} and Wolbink, {G. J.} and Dijkmans, {B. A. C.} and Aarden, {L. A.}",

year = "2008",

language = "Dutch",

volume = "152",

pages = "1672--1677",

journal = "Nederlands Tijdschrift voor Geneeskunde",

issn = "0028-2162",

publisher = "Vereniging Nederlands Tijdschrift voor Geneeskunde",

number = "30",

}

van der Laken, CJ , Voskuyl, AE, Roos, JC, Stigter van Walsum, M, de Groot, ER, Wolbink, GJ , Dijkmans, BAC & Aarden, LA 2008, 'Het ontstaan van immuuncomplexen van infliximab en anti-infliximab als een verklaring voor het falen van infliximabtherapie bij reumatoïde artritis: observationeel onderzoek bij 4 patiënten', Nederlands Tijdschrift voor Geneeskunde, vol. 152, no. 30, pp. 1672-1677.

Het ontstaan van immuuncomplexen van infliximab en anti-infliximab als een verklaring voor het falen van infliximabtherapie bij reumatoïde artritis: observationeel onderzoek bij 4 patiënten. / van der Laken, C. J.; Voskuyl, A. E.; Roos, J. C. et al.
In: Nederlands Tijdschrift voor Geneeskunde, Vol. 152, No. 30, 2008, p. 1672-1677.

Research output: Contribution to journal › Article › Professional

TY - JOUR

T1 - Het ontstaan van immuuncomplexen van infliximab en anti-infliximab als een verklaring voor het falen van infliximabtherapie bij reumatoïde artritis: observationeel onderzoek bij 4 patiënten

AU - van der Laken, C. J.

AU - Voskuyl, A. E.

AU - Roos, J. C.

AU - Stigter van Walsum, M.

AU - de Groot, E. R.

AU - Wolbink, G. J.

AU - Dijkmans, B. A. C.

AU - Aarden, L. A.

PY - 2008

Y1 - 2008

N2 - OBJECTIVE: To investigate the in vivo mechanism of non-responding to infliximab treatment of patients with rheumatoid arthritis (RA) and the role of anti-infliximab antibodies by using radiolabeled infliximab. DESIGN: Descriptive and comparative study. METHOD: Two responding and two non-responding RA patients were infused with radiolabeled infliximab. Subsequently imaging investigations and serum analysis were performed at set times. RESULTS: The scintigrams showed that the labelled infliximab was mainly present in the blood until 24 h after infusion. There was a trend of faster blood clearance and higher liver and spleen uptake of 99mTc-infliximab in one non-responding patient. Labelled infliximab was taken up by inflamed joints. The anti-infliximab level was high (1008 and 1641 U/ml) in the non-responders and low or not detectable in the responders. Sucrose gradients of serum revealed antibody complexes in both non-responders. Various sizes of antibody complexes, including very large ones, were observed in one non-responder who developed a serious infusion reaction. CONCLUSION: Infliximab-anti-infliximab immune complexes were found to form in RA non-responders due to the presence of significant quantities of anti-infliximab. This finding may partly explain the failure of the infliximab treatment

AB - OBJECTIVE: To investigate the in vivo mechanism of non-responding to infliximab treatment of patients with rheumatoid arthritis (RA) and the role of anti-infliximab antibodies by using radiolabeled infliximab. DESIGN: Descriptive and comparative study. METHOD: Two responding and two non-responding RA patients were infused with radiolabeled infliximab. Subsequently imaging investigations and serum analysis were performed at set times. RESULTS: The scintigrams showed that the labelled infliximab was mainly present in the blood until 24 h after infusion. There was a trend of faster blood clearance and higher liver and spleen uptake of 99mTc-infliximab in one non-responding patient. Labelled infliximab was taken up by inflamed joints. The anti-infliximab level was high (1008 and 1641 U/ml) in the non-responders and low or not detectable in the responders. Sucrose gradients of serum revealed antibody complexes in both non-responders. Various sizes of antibody complexes, including very large ones, were observed in one non-responder who developed a serious infusion reaction. CONCLUSION: Infliximab-anti-infliximab immune complexes were found to form in RA non-responders due to the presence of significant quantities of anti-infliximab. This finding may partly explain the failure of the infliximab treatment

M3 - Article

C2 - 18714521

SN - 0028-2162

VL - 152

SP - 1672

EP - 1677

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

IS - 30

ER -